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Abstract
Objective: To assess residual cervical intraepithelial neoplasia (CIN) 2/3 disease and clearance of high-risk (hr) human
papillomavirus (HPV) infections at 6 months after cryotherapy among HIV-positive women.
Design: Follow-up study.
Methods: 79 HIV-positive women received cryotherapy for CIN2/3 in Nairobi, Kenya, and underwent conventional cytology
6 months later. Biopsies were performed on high grade cytological lesions and hrHPV was assessed before (cervical cells and
biopsy) and after cryotherapy (cells).
Results: At 6 months after cryotherapy CIN2/3 had been eliminated in 61 women (77.2%; 95% Confidence Interval, (CI):
66.4–85.9). 18 women (22.8%) had residual CIN2/3, and all these women had hrHPV at baseline. CD4 count and duration of
combination antiretroviral therapy (cART) were not associated with residual CIN2/3. CIN3 instead of CIN2 was the only
significant risk factor for residual disease (odds ratio, OR vs CIN2 = 4.3; 95% CI: 1.2–15.0) among hrHPV-positive women after
adjustment for age and HPV16 infection. Persistence of hrHPV types previously detected in biopsies was found in 77.5% of
women and was associated with residual CIN2/3 (OR = 8.1, 95% CI: 0.9–70). The sensitivity, specificity, and negative
predictive value of hrHPV test in detecting residual CIN2/3 were 0.94, 0.36, and 0.96 respectively.
Conclusions: Nearly one quarter of HIV-positive women had residual CIN2/3 disease at 6 months after cryotherapy, and the
majority had persistent hrHPV. CD4 count and cART use were not associated with residual disease or hrHPV persistence. The
value of hrHPV testing in the detection of residual CIN2/3 was hampered by a low specificity.
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Little information is available on the efficacy of cryotherapy for
the treatment of CIN2/3 in HIV-positive women [6] and none
on the impact of cryotherapy on HPV persistence, i.e., a strong
risk factor for residual/recurrent disease in HIV-negative women
[4,5].
The aim of this study was to assess: 1) the frequency of
residual CIN2/3 disease and persistent infection of high-risk
(hr) HPV types at 6 months after cryotherapy for CIN2/3, and
2) the performance of hrHPV testing after cryotherapy in
the detection of residual disease in HIV-positive women in
Kenya.

Introduction
Women living with HIV are at increased risk for infection with
human papillomavirus (HPV), cervical intraepithelial neoplasia
grade 2 or 3 (CIN2/3) and invasive cervical cancer [1,2].
Residual or recurrent disease after CIN2/3 treatment is also
more frequent among HIV-positive women [3] than HIVnegative women [4,5].
Most studies of CIN2/3 in HIV-positive women reported
outcomes after excisional treatment, e.g. loop electrosurgical
excision procedure (LEEP), or cold knife conization (CKC) [3,6–
15]. However, cryotherapy is more feasible and affordable than
excisional treatment in low- and middle-income countries [16].
PLOS ONE | www.plosone.org
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Figure 1. Flowchart study population. HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia; cryo, cryotherapy; ASCUS, atypical
squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
doi:10.1371/journal.pone.0111037.g001

related conditions were invited to participate and were eligible if
they: 1) were between 18 and 55 years of age; 2) had not
undergone cervical screening in the last year; and 3) had never
been treated for cervical cancer or pre-cancerous lesions. After
obtaining a written informed consent, information on women’s
characteristics and the use of combined antiretroviral treatment
(cART) as well as blood samples to measure CD4 count were
collected. Cervical exfoliated cells (further on referred to as ‘‘cells’’)

Methods
Participants and study procedures
In 2009, 500 HIV-positive women in Nairobi, Kenya were
enrolled in a study that compared cervical cancer screening with
conventional cytology, visual inspection with acetic acid (VIA) and
HPV testing, as described elsewhere [17–19]. Briefly, women who
attended the Coptic Hope Center for Infectious Diseases for HIV-
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Table 1. Odds ratio (OR) and 95% confidence intervals (CI) for residual disease six months after cryotherapy (cryo) for CIN2/3 by
selected pre-treatment characteristics.1Kenya, 79 HIV-positive women.

Pre-cryo
characteristics

Total N

Cured
(#LSIL/CIN1)
n (%)

Total

79

61 (77.2)

Residual
disease
(CIN2/3)
n (%)
18 (22.8)

OR2
(95% CI)

OR3
(95% CI)

Age
,35

19

17 (89.5)

2 (10.5)

1

1

35–44

39

28 (71.8)

11 (28.2)

3.3 (0.7–16.9)

3.3 (0.6–19.4)

$45

21

16 (76.2)

5 (23.8)

2.7 (0.5–15.7)

2.2 (0.3–14.7)

p = 0.340

p = 0.543

x21 for trend
Parity
0–1

21

19 (90.5)

2 (9.5)

2

23

18 (78.3)

5 (21.7)

2.2 (0.4–13.6)

$3

35

24 (68.6)

11 (31.4)

3.5 (0.6–19.8)

x21 for trend

1

p = 0.153

CD4 cells/mL at baseline
.500

16

12 (75.0)

4 (25.0)

1

200–500

45

35 (77.8)

10 (22.2)

1.0 (0.3–4.0)

,200

18

14 (77.8)

4 (22.2)

x21 for trend

1.1 (0.2–6.0)
p = 0.891

CD4 count/mL at 6-month follow-up
$500

22

16 (72.7)

6 (27.3)

1.0

200–500

47

37 (78.7)

10 (21.3)

0.7 (0.2–2.6)

,200

10

8 (80.0)

2 (20.0)

0.8 (0.1–5.9)

x21 for trend

p = 0.750

cART
No

18

16 (88.9)

2 (11.1)

1

,2 years

37

28 (75.7)

9 (24.3)

2.1 (0.4–11.7)

$2 years

24

17 (70.8)

7 (29.2)

x21 for trend

2.5 (0.4–15.3)
p = 0.343

VIA
Neg

33

28 (84.9)

5 (15.2)

1

Pos

46

33 (71.7)

13 (28.3)

2.6 (0.8–8.6)

Normal/ASCUS/LSIL

25

23 (92.0)

2 (8.0)

1

HSIL or worse

52

36 (69.2)

16 (30.8)

5.2 (1.1–25.0)

Cytology4

Histology
CIN2

45

40 (88.9)

5 (11.1)

1

1

CIN3

34

21 (61.8)

13 (38.2)

5.3 (1.6–17.4)

4.3 (1.2–15.0)

Neg

18

18 (100)

0

1

Pos

61

43 (70.5)

18 (29.5)

‘ (1.9 - ‘)

Neg

64

53 (82.8)

11 (17.2)

1

1

Pos

15

8 (53.3)

7 (46.7)

3.9 (1.1–13.1)

2.2 (0.6–8.1)

hrHPV (cells)

HPV16 (cells)
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Table 1. Cont.

Residual
disease
(CIN2/3)
n (%)

OR2
(95% CI)

Total N

Cured
(#LSIL/CIN1)
n (%)

No

38

25 (65.8)

13 (34.2)

1

Yes

23

18 (78.3)

5 (21.7)

0.6 (0.2–1.9)

Pre-cryo
characteristics

OR3
(95% CI)

Multiple hrHPV5 (cells)

1

Unless otherwise specified;
Adjusted for age as appropriate;
Among 61 hrHPV-positive women only. Adjusted for age, histology and HPV16 as appropriate;
4
Do not add up to the total because of 2 indeterminate cytology results;
5
Among hrHPV-positive women only.
cART, combination antiretroviral therapy; VIA, visual inspection with acetic acid; hrHPV, high-risk human papillomavirus; ASCUS, atypical squamous cells of
undetermined significance; LSIL, low-grade squamous intraepithelial lesion; CIN, cervical intraepithelial neoplasia.
doi:10.1371/journal.pone.0111037.t001
2
3

read all of the cytological and histological slides. Cytology was
reported according to the Bethesda 1991 revised classification
[21].

were obtained using a Cervex-Brush (Rovers Medical Devices,
Oss, The Netherlands) and placed in PreservCyt media (Hologic,
Marlborough, MA, USA) for HPV testing. A medical doctor
performed a colposcopic examination and took a biopsy from all
women, either from the most abnormal area on the cervix
identified by the colposcopic examination, or at 12 o’clock if no
lesion was visualized. Biopsy tissues were immediately immersed in
10% buffered formalin and transported to the local pathology
laboratory, where they were embedded in paraffin. Biopsy tissues
and PreservCyt media were stored at ambient temperature and
shipped to the Department of Pathology at Vrije University
Medical Center (Amsterdam, the Netherlands) for HPV DNA
testing.
Women who were diagnosed with CIN2/3 disease by biopsy
were offered cryotherapy if the lesion was: 1) ,75% of the cervix
surface and not larger than the cryoprobe tip; and 2) entirely
visible and not extending by more than 2 to 3 mm into the
endocervical canal [20]. A follow-up visit was planned at 6 months
after cryotherapy. It included the collection of cells for conventional cytology and HPV testing and a blood sample for CD4
count. Women with high-grade squamous intraepithelial lesions
(HSIL) at cytology were offered a colposcopic examination
including a biopsy of the residual lesion. All cytological slides
and biopsies were processed under the supervision of the study
pathologist (FSR) at the Aga Khan University (Nairobi), who also

Ethics Statement
The study protocol was approved by the Ethical Review
Committees of the Kenyatta National Hospital, Kenya, the
University of Washington, the United States, and the International
Agency for Research on Cancer, France. The study conformed to
the Helsinki Declaration of 1975, as revised in 2000. Each
participant gave their written consent.

HPV DNA testing
HPV DNA testing was done on pre-cryotherapy cells and tissue
biopsies and exclusively on cells for the post-cryotherapy visit.
Biopsies were sectioned using a ‘sandwich’ approach, whereby
inner sections were used for HPV testing and outer sections for
histological examination. Testing methods have been described
elsewhere [17,22]. Briefly, detection of HPV DNA was done by
GP5+/6+-PCR followed by enzyme immunoassay detection with
a cocktail of oligonucleotide probes [23]. Subsequent HPV typing
was performed by reverse-line blot hybridization of PCR products
[24]. One pre-cryotherapy sample was negative for beta-globin,
but positive for hrHPV DNA, and it was included. HPV types 16,

Table 2. Presence of hrHPV after cryotherapy (cryo) by type of pre-cryo sample in women who were hrHPV-positive before
cryotherapy.

Post-cryo hrHPV status

Pre-cryo hrHPV-positive women

Cells

Cells n (%)

Biopsy n (%)

Persistent, HPV16

9 (14.8)

6 (12.2)

Persistent, other hr types1

40 (65.6)

32 (65.3)

New type(s) only2

5 (8.2)

6 (12.2)

Negative

7 (11.5)

5 (10.2)

Total

61

493

Kenya, 61 HIV-positive women.
1
Persistence of at least one hr type but not HPV16.
2
In the absence of persistent hr types.
3
Does not include 12 women who were hrHPV-positive in cells but negative in biopsy.
hrHPV, high-risk human papillomavirus.
doi:10.1371/journal.pone.0111037.t002
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Table 3. Crude odds ratio (OR) and 95% confidence intervals (CI) for residual disease six months after cryotherapy (cryo) for CIN2/3
by persistence of hrHPV infections detected in pre-cryo cells or biopsies.

Total n

Cured (#LSIL/CIN1) n (%)

Residual disease
(CIN2/3) n (%)

OR (95% CI)

No

12

11 (25.6)

1 (5.6)

1

Yes

49

32 (74.4)

17 (94.4)

5.8 (0.7–49.2)

Persistence of
hrHPV
Pre-cryo cells

Pre-cryo biopsies1
No

11

10 (32.3)

1 (5.6)

1

Yes

38

21 (67.7)

17 (94.4)

8.1 (0.9–69.7)

Kenya, 61 HIV-positive women.
Does not include 12 women who were hrHPV-positive in cells but negative in biopsy.
hrHPV, high-risk human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; CIN, cervical intraepithelial neoplasia.
doi:10.1371/journal.pone.0111037.t003
1

visit. Sixty-one women who had either cytology # LSIL or biopsy
# CIN1 were considered cured (Figure 1).
The median age of 79 women eventually included in the present
report was 41 years (IQR: 35–45). At baseline, 61 (77.2%) of them
were using cART, and 6 had started cART between the baseline
and follow-up visit. Median CD4 count was lower at baseline (322
cells/mL, IQR: 205–477) than at the follow-up visit (386, IQR:
272–558) (p = 0.007).
Table 1 shows OR for residual CIN2/3 by selected baseline
characteristics. Cryotherapy eliminated CIN2/3 in 77.2% (95%
CI: 66.4–85.9) of all women (Table 1). The presence of HSIL
cytology (OR vs # LSIL = 5.2; 95% CI: 1.1–25.0); CIN3 in biopsy
(OR vs CIN2 = 5.3; 95% CI: 1.6–17.4); infection with hrHPV
(OR = ‘; 95% CI: 1.9-‘), and HPV16 (OR = 3.9; 95% CI: 1.1–
13.1) in cells at baseline were significantly associated with residual
disease in the age-adjusted models. Parity, CD4 cell count,
duration of cART use, diagnosis at VIA, and multiple hrHPV
infections at baseline (37.7% of hrHPV-positive women) were
unrelated to residual disease. Residual disease was only found
among 61 women who were hrHPV-positive at baseline and,
among them, 70.5% (95% CI: 57.4–81.5%) were cured. The
presence of CIN3 instead of CIN2 at baseline was significantly
associated with residual disease (OR vs CIN2 = 4.3; 95% CI: 1.2–
15.0) after adjustment for age and HPV16 infection (Table 1).
After cryotherapy, hrHPV infection in cells was detected in 56
(70.9%) women, of whom 22 (39.3%) had multiple hrHPV types,
and 2 were new infections in women who were previously hrHPVnegative. A comparison of hrHPV findings at baseline and 6
months after cryotherapy among women who were initially
hrHPV-positive in cells (n = 61) or biopsies (n = 49) is shown in
Table 2. Persistence of at least one hrHPV type in cells was
detected in 80.4% of women, including persistence of HPV16 in
14.8%. New hrHPV types, in the lack of persistent types, were
detected in 5 women whereas 7 (11.5%) had become hrHPVnegative. Similar proportions of persistence were found when the
comparison was based on hrHPV types detected in pre-treatment
CIN2/3 biopsies (Table 2). The persistence of HPV16 or other
hrHPV types was not influenced by CD4 count or duration of
cART use (data not shown).
Table 3 shows OR for residual disease according to the
presence of persistent hrHPV infection after cryotherapy. Women
with persistent infection showed an increased risk of residual
disease. ORs were 5.8 (95% CI: 0.7–49.2); and 8.1 (95% CI: 0.9–
69.7) for persistence of types previously detected in baseline cells or
biopsy, respectively. The level of persistence of hrHPV infections

18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 were considered
hr types [25].

Statistical analysis
Women with either histologically confirmed CIN2 or CIN3
were classified as having residual disease; women with either
cytology # low-grade squamous intraepithelial lesion (LSIL) or
biopsy # CIN1 were classified as cured. Women’s CD4 counts at
baseline and at 6-month follow-up were compared using the
Wilcoxon signed-rank test.
Age-adjusted odds ratios (ORs) for the presence of residual
disease and the corresponding 95% confidence intervals (CIs) were
computed. None of the hrHPV-negative women had residual
disease. A multiple logistic regression model including age and
significant residual disease risk factors was therefore restricted to
hrHPV-positive women. In addition, cytology and histology at
baseline were closely correlated and we chose to include only
histology. Tests for linear trend of ORs were computed giving
increasing scores to each level of the categorized variable and
fitting them into the model as continuous variables.
The persistence of HPV16, hrHPV types other than HPV16,
and the appearance of new hrHPV types were assessed by
comparing hrHPV findings from cells or biopsies collected at the
pre-cryotherapy visit with those in cells at the post-cryotherapy
visit. Crude ORs for residual disease by hrHPV persistence after
cryotherapy were computed. Finally, we evaluated the performance of hrHPV testing at 6 months after cryotherapy (sensitivity,
specificity, positive predictive value, PPV, and negative predictive
value, NPV) for the detection of residual CIN2/3.

Results
Of the 500 women who were enrolled in our study, 498 had an
adequate cell sample (Figure 1). CIN2 and CIN3 were detected in
66 and 47 women, respectively, and 101 received cryotherapy 30
days on average after inclusion in the study. A follow-up visit was
scheduled at 6 months after cryotherapy (median: 182 days,
Interquartile range, IQR: 165–197). Fifteen women (11 CIN2 and
4 CIN3) did not attend the follow-up visit and one woman with
CIN3 underwent hysterectomy. Out of the remaining 85 women,
81 had a valid cytology and 26 had HSIL. All but two women with
HSIL underwent colposcopic examination and biopsy collection.
Among 18 women with residual disease, 5 had CIN2 and 13
CIN3. Only 17 women had negative cytology at the follow-up
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was unrelated to the level of CD4 count or the use of cART (data
not shown). None of the five women with new hrHPV types in the
lack of persistent infection showed residual disease (data not
shown).
The performance of post-treatment hrHPV testing to detect
residual disease is shown in Table 4. The sensitivity and specificity
of hrHPV testing at 6 months after cryotherapy were 0.94 and
0.36, respectively; PPV and NPV were 0.30 and 0.96, respectively.
Testing for either or both HPV16 and 18 showed lower sensitivity
and NPV than hrHPV testing, but better specificity and PPV
(except for HPV18 only). Persistent hrHPV infection showed
sensitivity, specificity, PPV and NPV of 0.94, 0.48, 0.35 and 0.97,
respectively.

11

17

HPV16/18

Persistent hrHPV1

PLOS ONE | www.plosone.org

Kenya, 79 HIV-positive women.
1
At least 1 same hrHPV type present before and 6 months after cryotherapy.
TP, true positive, FP, false positive, FN, false negative, TN, true negative, PPV, positive predictive value, NPV, negative predictive value, hrHPV, high-risk human papillomavirus.
doi:10.1371/journal.pone.0111037.t004

0.97 (0.83–1.00)
0.35 (0.22–0.50)
0.48 (0.35–0.61)
0.94 (0.73–1.00)
29
1
32

0.79 (0.67–0.88)

0.87 (0.75–0.95)
0.44 (0.24–0.65)
0.77 (0.65–0.87)
0.61 (0.36–0.83)
47
7

0.83 (0.72–0.91)

4

14

0.33 (0.10–0.65)
0.87 (0.76–0.94)
0.22 (0.06–0.48)
53
14

0.96 (0.78–1.00)

HPV18

8

0.54 (0.25–0.81)

0.30 (.19–0.44)
0.36 (0.24–0.49)

0.90 (0.80–0.96)
0.39 (0.17–0.64)

0.94 (0.73–1.00)
22

55
11

1

7
HPV16

6

17
hrHPV

39

Specificity
Sensitivity
TN
FN
FP
TP
Post- treatment

Table 4. Performance of hrHPV testing for the detection of CIN2/3 six months after cryotherapy.

PPV

NPV
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Discussion
Our study on the efficacy of cryotherapy for the treatment of
CIN2/3 in HIV-positive women is one of the few that included
cytological and histological evaluation prior to and after treatment
and information on treatment outcome by persistence of
individual hrHPV types. Cryotherapy eliminated CIN2/3 in
77% (95% CI: 66–86) of all women and 71% (95% CI: 57–82%)
of women who had hrHPV infection before treatment, but only a
small minority of them became hrHPV-negative. Contrary to
others [8,11,13,26], we chose to define as cure the elimination of
CIN2/3 rather than the disappearance of any cytological
abnormalities. If we had used normal cytology as threshold, only
19 (24.1%) of our study women would have been considered
cured. However, on account of the difficulty to eliminate HPV
infection and its morphological correlate (low-grade lesions) in
HIV-positive women, we reasoned that the cure of CIN2/3 had to
be considered the most important outcome.
An initial diagnosis of CIN3, instead of CIN2, was the most
important predictor of residual disease. HPV16-positivity at
baseline was not significantly associated with residual disease after
adjustment for the presence of CIN3. Infections with multiple
hrHPV types were relatively frequent (38%) in study women but
they did not increase the probability of residual disease as expected
since cancer progression-prone CIN2/3 are assumed to be
monoclonal [27,28]. No residual disease was found among 18
women who were initially hrHPV-negative.
Some [8,11,13,26], but not all studies [3,9,12], reported that
cART treatment or high CD4 counts were favourable prognostic
factors for treatment outcome. In our cross-sectional study, neither
cART use nor CD4 counts prior to or after cryotherapy were
associated with residual disease. Unfortunately, we did not have
systematic information on CD4 count prior to cART. However,
cART tended to be started relatively late in Kenya in 2009 (i.e,
CD4 count ,250 cells/mL or presence of WHO clinical III/IV
stage disease) [29], when CIN2/3 may have already become
refractory to immune reconstitution [17].
Our study confirms that residual disease after excisional
treatment or cryotherapy of CIN2/3 may be more frequent
among HIV-positive women than HIV-negative women. A study
from Zimbabwe [6] reported residual CIN2/3 at 6 months after
cryotherapy or LEEP in 3.8% and 1.8% of 109 HIV-positive
women, respectively, but in none of 38 HIV-negative women. A
few additional reports mainly from high-income countries
included only HIV-positive women and consistently showed the
difficulty in achieving cure of CIN2/3 and avoiding long-term
recurrences in HIV-positive women. Tebeu et al [30] reviewed
early studies on the outcome of conization for any degree of CIN
in HIV-positive women at 6-to-74 months after treatment.
Recurrences ranged between 20% and 75% but residual CIN1
6
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was not separated from CIN2/3. Heard et al [11] reported that
54% of 75 HIV-positive women treated with LEEP or conization
in France had a CIN recurrence at 36 months, and approximately
one third had CIN2/3. Massad et al [26] reported residual CIN2/
3 disease in 12% of 115 mostly HIV-positive women mainly
treated with excisional methods in the United States. Reimers et al
[3] detected residual CIN2/3 in 42% of 75 HIV-positive women
at 6 months after LEEP or CKC.
Rates of residual disease and recurrences in HIV-negative
women after CIN2/3 treatment were reported in many studies
[31,32]. One study of 610 women from the United States showed
residual CIN2/3 at 6 months after LEEP in 3% of women, and
7% after 2 years [4]. In other studies in which excisional methods
were used for CIN2/3 treatment, residual disease ranged between
1% to 8% at 6 months [33,34], and between 2% and 20% at 2
years [33,35,36] or more [37]. A few studies from India [38,39]
and Africa [6] showed persistent or recurrent diseases in 13% or
less of HIV-negative women at 2 years or more after cryotherapy.
The difference in hrHPV clearance between HIV-positive and
HIV-negative women after CIN2/3 treatment is much larger than
the difference in the frequency of residual disease. Positivity for
hrHPV after LEEP was shown in 57% of HIV-positive women
with any degree of CIN by Gingelmaier et al [10] in Germany.
The proportion of HIV-negative women who were hrHPVpositive at 6 months after treatment in PCR-based studies was 10
to 37% [4,37,40–42], except in studies that used ultra-sensitive
HPV tests [33,36]. Type-specific hrHPV persistence in our study
(80%) was also larger than that reported after cryotherapy or
excisional treatment among HIV-negative women (7-to-37%)
[4,40,43]. The association between persistent hrHPV infection
and residual disease in our study was especially strong (8-fold
increase, of borderline statistical significance) when the persistent
type was the one previously detected in the CIN2/CIN3 biopsy.
A positive association between persistent HPV infection and
residual or recurrent CIN2/3 was shown in HIV-negative women
[4,37,41,44] lending support to the use of HPV testing to detect
treatment failure [31]. In fact, HPV testing was shown to be more
sensitive and not significantly less specific than cytology screening
in a large meta-analysis that excluded verification bias [31]. The
sensitivity of hrHPV testing in our study (94%) was similar to the
corresponding sensitivity in HIV-negative women (92%) [31] but
specificity (36%) was much lower than among HIV-negative
women (76%) [31]. Sensitivity did not change but specificity
improved to 48% when we used persistent hrHPV infection
instead of hrHPV-positivity after cryotherapy. Testing for HPV16
and/or 18 showed a specificity of 77% but a sensitivity of only
61%. An equally valid evaluation of the performance of cytology

testing in HIV-positive women was impossible in our study due to
verification bias, as only women with HSIL cytology received
colposcopic examination.
Limitations of our study include the lack of random biopsies at
follow-up visit and the short follow-up. A 6-month follow-up
prevented the evaluation of long-term recurrences after cryotherapy in HIV-positive women and lends support to the interpretation of treatment failures as residual disease. Infections with new
hrHPV types were seldom detected. We were also unable to
compare the efficacy of cryotherapy to excisional methods as they
were used only exceptionally. However, a meta-analysis [32] did
not show systematic differences across seven different techniques of
CIN treatment, including cryotherapy, in HIV-negative women.
Strengths of our study include the use of high-quality cytological
and histological examination and a clinically validated HPV
testing method [45] on pre- and post-treatment cells and pretreatment CIN2/3 biopsies.
In conclusion, we demonstrated that cryotherapy eliminated
three quarters of CIN2/3, but only one fifth of hrHPV infections
in HIV-positive women. HIV-positive women should be, therefore, carefully monitored after cryotherapy as they often remain
cytologically abnormal and hrHPV-positive. In fact, the value of
testing for hrHPV infection to detect residual CIN2/3 after
cryotherapy was hampered by the lower specificity of the test than
in HIV-negative women. The clinical implications of low hrHPV
clearance will require further study and so will the assessment of
the possible influence of long-term history of cART use and CD4
count on recurrence rates.
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